MENU
IRD
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Opus Genetics (IRD) Ownership - Who owns Opus Genetics?
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders... Show more
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
60.26M
P/E Ratio
N/A
Total Cash
36.64M
Projected Growth
N/A
Total Debt
N/A
Revenue
8.38M
Risk (Beta)
0.96
Dividend Yield
N/A
Total Cash/Share
0.61
Total Debt/Equity
N/A
Revenue/Share
0.47 USD as % of share price
Fundamentals
IRD
Capitalization
60.3M
P/E Ratio
N/A
Risk (Beta)
0.96
Dividend Yield
N/A
Total Cash
36.6M
Total Cash/Share
0.61
Total Debt
N/A
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.47%
Revenue
8.38M
ROE
N/A
Book Value
34.3M
P/B Ratio
11.88
Cash Flow
N/A
Earnings
-1.09
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
3K
Current Ratio
6.63
Current Revenue Per Employee
276214.28
Dividends Per Share - Security
N/A
EBITDA
-28.52M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-57.50
Shares Held By Institutions
5.89M
Shares Outstanding - Current
59.7M
Total Liabilities
6.09M
Total Volume MTD
N/A
Value
-1
Gain YTD
-15.546
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics
Industry Biotechnology
Profile
Fundamentals
Details